Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ficerafusp alfa by Bicara Therapeutics for Colorectal Cancer: Likelihood of Approval
Ficerafusp alfa is under clinical development by Bicara Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData,...
Ficerafusp alfa by Bicara Therapeutics for Pancreatic Cancer: Likelihood of Approval
Ficerafusp alfa is under clinical development by Bicara Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Ficerafusp alfa by Bicara Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Ficerafusp alfa is under clinical development by Bicara Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC)....